Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation

Exclusion Criteria

• •A smoking history of more than or equal to 10 years or having smoked within 6 months of screening visit
• •Upper respiratory tract infections within 2 weeks or lower respiratory tract infection within 4 weeks prior to screening visit
• •Asthma exacerbations that required emergency care or a hospital stay within 4 weeks prior to screening visit
• •Any current or recent respiratory tract infections that might affect the response to the study drug as determined by the investigator, including cystic fibrosis, bronchiectasis, tuberculosis, emphysema and other significant respiratory diseases besides asthma
• •Current clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine, psychiatric, malignant or other illnesses that could impact the study as determined by the investigator
• •Known intolerance or hypersensitivity to any ingredients of the study drug DPI or Proventil MDI (i.e.: Albuterol, sulfate, lactose, milk protein, HFA-134a, oleic acid and ethanol)